/
Pipeline Programs↗
Active Trials↗
Companies Involved↗
Lymphoid Malignancies is an emerging landscape with 12 programs across 19 companies. The most active players are AVM Biotechnology Inc.
Intelligence
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Bubble size = clinical trials
Key Players
Pipeline
Analysis
83%
Small molecule
10 of 12 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 12 classified programs, each share of the total. Modality classified for 100% of 12 pipeline programs.
Analysis
58
clinical trials
Clinical Trials
58 trials
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)